Small molecule inhibitor of RIPK3-MLKL protein-protein interaction for necroptosis-associated neurodegeneration

Overview

This solution offers a targeted small molecule inhibitor designed to disrupt the RIPK3-MLKL protein-protein interaction, a critical step in the necroptosis pathway. Necroptosis is a regulated form of neuroinflammatory cell death implicated in multiple neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Because necroptosis cannot proceed without RIPK3 and MLKL, therapeutic intervention at this protein-protein interaction point offers broader clinical relevance than targeting upstream regulators. The lead compound has demonstrated efficacy in both biochemical and in vivo studies, positioning it as a promising candidate for treating neurodegenerative and neuroinflammatory conditions.

Technical specifications

• Mechanism of action: ATP uncompetitive inhibitor and MLKL competitive inhibitor that disrupts the RIPK3-MLKL protein-protein interaction, blocking necroptosis at a key downstream checkpoint
• Discovery approach: Identified through in silico docking screen targeting the RIPK3-MLKL binding interface
• Biochemical validation: Radiometric kinetic assays confirmed dual inhibitory mechanism; microscale thermophoresis demonstrated inhibition of RIPK3-MLKL binding
• Cellular validation: Inhibition of necroptosis confirmed via flow cytometry, western blot, immunoprecipitation, and cell viability assays in necroptosis-induced HT-29 cells
• In vivo validation: Acute respiratory distress syndrome mouse model showed significantly decreased bronchoalveolar lavage cell counts, protein levels, and lung tissue damage at 20 mg/kg dosing compared to controls
• Current development: Structure-activity relationship studies underway to develop novel chemical analogs with improved inhibitory capability and blood-brain barrier penetrance, with future testing planned in Alzheimer's disease patient-derived iPSCs

Technology readiness level

The technology is currently at a preclinical stage of development. The lead compound has been validated through in vitro biochemical assays, cell-based assays in necroptosis models, and an in vivo mouse model of acute respiratory distress syndrome. Current efforts are focused on medicinal chemistry optimization through structure-activity relationship studies to improve potency and blood-brain barrier penetration, followed by evaluation in patient-derived induced pluripotent stem cells. Chemical synthesis and compound testing are expected to be completed within 1–1.5 years, with the goal of advancing toward neurodegenerative disease models.